OKLAHOMA BOARD OF NURSING

2915 North Classen Boulevard, Suite 524 Oklahoma City, OK 73106 405-962-1800

CRNA Inclusionary Formulary

To be granted authority to select, order, obtain and administer drugs, Certified Registered Nurse Anesthetists (CRNAs) must hold a current Registered Nurse license, be recognized as a CRNA in Oklahoma and meet the continuing education requirements noted in the *Rules of the Oklahoma Board of Nursing*, specifically 485:10-18-2. Pursuant to 59 O.S. § 567.3a.10 [Oklahoma Nursing Practice Act], a Formulary Advisory Council has been established to develop and submit to the Board recommendations for an inclusionary formulary.

The following Board-approved *CRNA Inclusionary Formulary* lists drugs that may be ordered, selected, obtained or administered during the **perioperative** and **periobstetrical** periods by CRNAs who have been granted authority by the Board to select, order, obtain, and administer drugs.

4:00 Antihistamine Drugs

4:04 First Generation Antihistamines

Diphenhydramine Hydrochloride

Promethazine Hydrochloride (see also 28:24.92 and 28:16.08.24) [CAUTION:

Be aware of pediatric restrictions (Not to be administered to children under the age of two years).]

[CAUTION: Be aware of the FDA Boxed Warning on IV use (limit the drug's concentration and rate of administration and ensure a properly functioning intravenous line).]

12:00 Autonomic Drugs

12:04 Parasympathomimetic (Cholinergic) Agents

Neostigmine Bromide

Physotigmine Salicylate

Pyridostigmine Bromide

12:08 Anticholinergic Agents

12:08.08 Antimuscarinics/antispasmodics

Atropine

Glycopyrrolate

Ipratropium Bromide

Scopolomine*

12:12 Sympathomimetic (Adrenergic) Agents

12:12.04 α-Adrenergic Agents

Midodrine*

Phenylephrine

12:12.08 β-Adrenergic Agonists

12:12.08.04 Non-selective β-Adrenergic Agonists

Isoproterenol

Board Approved: 1/20/98

OBN Policy/Guideline - #P50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06

Page 1 of 10

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11;

5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16

12:12.08.08 Selective β₁-Adrenergic Agonists

Dobutamine

Dopamine

12:12.08.12 Selective β₂-Adrenergic Agonists

Albuterol/Levalbuterol

Formoterol

Metaproterenol*

Salmeterol

Terbutaline Sulfate

Indacterol

12:12.12 α- and β-Adrenergic Agonists

Ephedrine

Epinephrine

Metaraminol*

Norepinephrine

Pseudoephedrine

12:16 Sympatholytic (Adrenergic Blocking) Agents

12:16.04 <u>α-Adrenergic Blocking Agents</u>

12:16.04.04 Non-selective α-Adrenergic Blocking Agents

Phentolamine

12:20 <u>Skeletal Muscle Relaxants</u> (all intravenous future new drugs approved)

12:20.08 Direct-acting Skeletal Muscle Relaxants

Dantrolene Sodium

12:20.20 Neuromuscular Blocking Agents

Atracurium Besylate

Pancuronium Bromide

Rocuronium Bromide

Succinylcholine Chloride

Vecuronium Bromide

Cisatracurium

16:00 Blood Derivatives

Albumin Human

Plasma Protein Fraction*

Blood and Blood Components (not in AHFS)

20:00 Blood Formation and Coagulation

20:12 Antithrombotic Agents

20:12.04 Anticoagulants

20:12.04.16 Heparins

Enoxaparin

Heparin

20:28 Antihemorrhagic Agents

20:28.08 Antiheparin Agents

Protamine Sulfate

20:28.16 Hemostatics

Aminocaproic Acid

Board Approved: 1/20/98

OBN Policy/Guideline - #P50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06

Page 2 of 10

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11;

5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16

Tranexamic (TXA)

20:28.92 Antihemorrhagic Agents, Misc.

Idarucizumab

24:00 Cardiovascular Drugs

24:04 Cardiac Drugs

24:04.04 Antiarrhythmic Agents

24:04.04.04 Class Ia Antiarrhythmics

Disopyramide

Procainamide

Quinidine

24:04.04.08 Class Ib Antiarrhythmics

Lidocaine

24:04.04.20 Class III Antiarrhythmics

Amiodarone

24:04.04.24 Class IV Antiarrhythmics

Adenosine

24:04.08 Cardiotonic Agents

Digoxin

24:08 Hypotensive Agents

24:08.16 Central α-Agonists

Clonidine

Methyldopa

24:08.20 Direct Vasodilators

Hydralazine

Sodium Nitroprusside

24:12 Vasodilating Agents

24:12.08 Nitrates and Nitrites

Nitrogylcerine

24:24 β-Adrenergic Blocking Agents

Atenolol

Esmolol Hydrochloride*

Labetalol

Metoprolol

Nadolol*

Propranolol

24:28 Calcium-Channel Blocking Agents

24:28.08 Dihydropyridines

Nicardipine

Nifedipine

24:28.92 Calcium-Channel Blocking Agents, Miscellaneous

Verapamil

24:32 Renin-Angiotensin-Aldosterone System Inhibitors

24:32.04 Angiotensin-Converting Enzyme Inhibitors

Captopril

Enalaprilat/Enalapril

Board Approved: 1/20/98 OBN Policy/Guideline - #P50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06

Page 3 of 10

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11;

5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16

28:00 Central Nervous System Agents

28:04 General Anesthetics (all in this class approved including future new drugs)

28:04.04 Barbiturates

Methohexital*

28:04.16 Inhalation Anesthetics (not in AHFS)

28:04.92 General Anesthetics, Miscellaneous

Etomidate

Ketamine**

Fospropofol

Propofol

28:08 Analgesics and Antipyretics

28:08.04 Nonsteroidal Antiflammatory Agents

28:08.04.08 Cyclooxygenase-2 (COX-2) Inhibitors

Celecoxib

28:08.04.24 Salicylates

Aspirin

28:08.04.92 Other Nonsteroidal Anti-inflammatory Agents

Ibuprofen (PO or IV)

Indomethacin

Ketorolac

28:08.08 Opiate Agonists (all in this class approved including future new drugs)

Codeine*** [NOTE: Be aware of PEDIATRIC CAUTION, FDA Drug safety communication new Boxed Warning on use after tonsillectomy or adenoidectomy 2/20/2013]***

Fentanyl

Hydrocodone

Hydromorphone

Levorphanol*

Meperidine

Morphine

Remifentanil*

Sufentanil Citrate

Tramadol

28:08.12 Opiate Partial Agonists (all in this class approved including future new

drugs)

Buprenorphine

Butorphanol

Nalbuphine*

28:08.92 Analgesics and Antipyretic, Miscellaneous

Acetaminophen (PO or IV)

Sodium Thiosalicylate*

28:10 Opiate Antagonists (all in this class approved including future new drugs)

Nalmefene*

Naloxone

Naltrexone

Board Approved: 1/20/98

OBN Policy/Guideline - #P50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06

Page 4 of 10

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11;

5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16

28:12 Anticonvulsants

28:12.04 Barbituates

Phenobarbital

28:12.08 Benzodiazepines

Clonazepam

28:12:12 Hydantoins

Ethotoin*

Fosphenytoin

Phenytoin

28:12.92 Anticonvulsants, Miscellaneous

Carbamazepine

Felbamate*

Gabapentin

Lamotrigine

Magnesium Sulfate

Valproate/Divalproex

28:16 Psychotherapeutic Agents

28:16.08 Antipsychotics

28:16.08.04 Atypical Antipsychotics

28:16.08.08 Butyrophenones

Haloperidol

28:16.08.24 Phenothiazines

Prochlorperazine

Perphenazine*

28:20 Anorexigenic Agents and Respiratory and CNS Stimulants

28:20.32 Respiratory and CNS Stimulants

Caffeine/Caffeine and Sodium Benzoate

Doxapram*

28:24 Anxiolytics, Sedatives, and Hypnotics

28:24.04 Barbiturates* (all in this class approved including future new drugs)

Phenobarbital*

28:24.08 Benzodiazepines (all in this class approved including future new drugs)

Alprazolam

Chlordiazepoxide

Diazepam

Lorazepam

Midazolam

Temazepam*

28:24.92 Anxiolytics, Sedatives, and Hypnotics, Miscellaneous

Dexmedetomidine

Hydroxyzine

Promethazine

28:36 Antiparkinsonian Agents

28:36.08 Anticholinergic Agents

Benztropine Mesylate

28:92 Central Nervous System Agents, Miscellaneous

Flumazenil

Board Approved: 1/20/98

OBN Policy/Guideline - #P50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06

Page 5 of 10

 $Board\ Revised:\ 9/30/99;\ 5/25/01;\ 5/28/02;\ 5/27/03;\ 5/25/04;\ 5/24/05;\ 5/29/07;\ 5/27/08;\ 5/19/09;\ 5/25/10;\ 7/26/11;$

5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16

36:00 Diagnostic Agents

36:40 Kidney Function

Indigo Carmine (Indigotindisulfonate)*

36:56 Myasthenia Gravis

Edrophonium Chloride*

40:00 Electrolytic, Caloric, and Water Balance

40:08 Alkalinizing Agents

Citrate Salts

Sodium Bicarbonate

Sodium Lactate*

40:12 Replacement Preparations

Calcium Salts

Dextran 40*

Dextran75 (not in AHFS) [CAUTION: Potential complication of anaphylactic reaction to Dextran 75]

Electrolyte Solutions*

Hetastarch [CAUTION: Potential complication of anaphylactic reaction to Hetastarch in patients allergic to corn] [AVOID use with renal compromised patients]

Potassium Supplements

Sodium Chloride

40:20 Caloric Agents

Dextrose*

Invert Sugar*

40:24 Salt and Sugar Substitutes (not in AHFS)

40:28 Diuretics

40:28.08 Loop Diuretics

Bumetanide

Furosemide

40:28.12 Osmotic Diuretics

Mannitol

40:28.20 Thiazide Diuretics

Chlorothiazide

48:00 Respiratory Tract Agents (all in this class approved including future new drugs)

48:08 Antitussives

Benzonatate*

Codeine

Dextromethorphan

Hydrocodone

48:16 Expectorants

Guaifenesin

Potassium Iodide (see also 68:36.08)

48:24 Mucolytic Agents

Acetylcysteine (see also 92:12)

Board Approved: 1/20/98

OBN Policy/Guideline - #P50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06

Page 6 of 10

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11;

5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16

52:00 Eye, Ear, Nose, and Throat (EENT) Preparations

52:16 Local Anesthetics

Benzocaine

Dyclonine*

Proparacaine

Tetracaine*

52:32 Vasoconstrictors

Epinephrine*

Naphazoline*

Oxymetazoline*

Phenylephrine*

Propylhexedrine*

Tetrahydrolozine*

52:40 Antiglaucoma Agents

52:40.12 Carbonic Anhydrase Inhibitors

Acetazolamide

56:00 Gastrointestinal Drugs

56:04 Antacids and Adsorbents

Aluminum Carbonate

Aluminum Hydroxide

Aluminum Phosphate

Antacids

Calcium Carbonate

Charcoal, Activated

Dihydroxyaluminum Aminoacetate

Dihydroxyaluminum Sodium Carbonate

Magaldrate

Magnesium Carbonate

Magnesium Hydroxide

Magnesium Oxide

Magnesium Trisilicate

Sodium Bicarbonate

56:22 Antiemetics

56:22.08 Antihistamines

Dimenhydrinate

Meclizine

Prochlorperazine

Trimethobenzamide*

56:22.20 5-HT₃ Receptor Antagonists

Dolasetron

Granisetron

Ondansetron

56:22.92 Antiemetics, Miscellaneous

Aprepitant/Fosaprepitant

56:28 Antiulcer Agents and Acid Suppressants

Board Approved: 1/20/98

OBN Policy/Guideline - #P50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06

Page 7 of 10

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11;

5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16

56:28.12 Histamine H2-Antagonists

Cimetidine*

Famotidine

Nizatidine*

Ranitidine

56:28.32 Protectants

Sucralfate

56:28.36 Proton-pump Inhibitors

Dexlansoprazole

Esomeprazole

Lansoprazole

Omeprazole

Pantoprazole

Rabeprazole

56:32 Prokinetic Agents

Metoclopramide

68:00 Hormones and Synthetic Substitutes

68:04 Adrenals (all in this class approved including future new drugs)

Beclomethasone

Betamethasone*

Cortisone Acetate

Dexamethasone

Fludrocortisone*

Flunisolide

Hydrocortisone

Methlyprednisolone

Prednisolone

Prednisone

Triamcinolone

68:20 Antidiabetic Agents

68:20.08 Insulins

Insulin Aspart

Insulin Glargine

Insulin Human

Insulin, Isophane (not in AHFS)

Insulin Lispro

Insulin Zinc*

68:20.20 Sulfonylureas

Chlorpropamide*

Glimepiride

Glipizide

Glyburide

Tolazamide*

Tolbutamide*

68:22 Antihypoglycemic Agents

68:22.12 Glycogenolytic Agents

Glucagon

Board Approved: 1/20/98

OBN Policy/Guideline - #P50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06

Page 8 of 10

 $Board\ Revised:\ 9/30/99;\ 5/25/01;\ 5/28/02;\ 5/27/03;\ 5/25/04;\ 5/24/05;\ 5/29/07;\ 5/27/08;\ 5/19/09;\ 5/25/10;\ 7/26/11;$

5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16

68:28 Pituitary

Corticotropin Desmopressin

Vasopressin

72:00 Local Anesthetics (all in this class approved including future new drugs)

Articaine

Bupivacaine

Chloroprocaine

Lidocaine

Mepivacaine

Prilocaine

Procaine (not in AHFS)

Ropivacaine (not in AHFS)

Tetracaine

76:00 Oxytocics

Carboprost Tromethamine*

Dinoprostone

Ergonovine/Methergonovine

Oxytocin

Sodium Chloride 20% Injection

Urea 40-50% Injection

84:00 Skin and Mucous Membrane Agents

84:04 Anti-infective

84:04.92 Local Anti-Infectives, Miscellaneous

Chlorhexidine gluconate*

84:08 Antiprurities and Local Anesthetics (all in this class approved including future

new drugs)

Benzocaine*

Dibucaine*

Doxepin*

Ethyl Chloride*

Phenazopyridine*

Pramoxine*

86:00 Smooth Muscle Relaxants

86:16 Respiratory Smooth Muscle Relaxants

Aminophylline

Theophyllines

92:00 Miscellaneous Therapeutic Agents

92:12 Antidotes

Acetylcysteine

Methylene Blue

Sugammadex

Board Approved: 1/20/98

OBN Policy/Guideline - #P50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06

Page 9 of 10

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11;

5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16

92:92 Other Miscellaneous Therapeutic Agents Adenosine Phosphate*

[NOTE: ACLS Algorithm medications are listed according to the classification system in the AHFS Drug Information resource.]

Regulatory Authority:

59 O.S. §567.4b. C.

Reference:

American Hospital Formulary Service®. AHFS Drug Information (2016). Published by Authority of the Board of the American Society of Health-System Pharmacists®, Bethesda, MD.

*Omitted from the print version of AHFS Drug Information because of space limitations, as stated by the publisher. May view the AHFS Drug Information website: http://www.ahfsdruginformation.com

**Reference for Ketamine: http://reference.medscape.com/drug/ketalar-ketamine-343099

*** Reference for Codeine precautions: http://www.fda.gov/Drugs/DrugSafety/ucm313631.htm

Board Approved: 1/20/98 OBN Policy/Guideline - #P50A Board Reviewed w/o Revision: 1/28/99; 5/23/06 Page 10 of 10

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11;

5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16